Cannabis Consumption & Driving Impairment Assessment on a Closed Course

Status Recruiting

Clinical Trial Summary

In a true experiment, roughly 300 volunteer participants will smoke active cannabis, a corresponding placebo, or no substance at all (control). Next, participants will complete a drive test and then be observed by actual California Highway Patrol (CHP) officers who will attempt to classify participants as impaired or unimpaired. CHP Officers will evaluate participants in the context of driving (i.e., while following participants in an actual patrol car), as part of a roadside behavioral assessment (i.e., the Advanced Roadside Impaired Driving Enforcement, or ARIDE, battery, which includes Standardized Field Sobriety Tests, or SFSTs), and as part of a Drug Recognition Expert (DRE) evaluation conducted indoors.

Clinical Trial Description

The easing of restrictions on the use of cannabis for recreational purposes presents a new challenge for policing of impaired driving, which is to say Driving Under the Influence of Drugs (DUI-D), specifically cannabis. In particular, it is not entirely clear how well the tools used by law enforcement officers to detect driving impairment (e.g., behavioral instruments such as the SFSTs, as included in the ARIDE battery) work for identifying cannabis-induced driving impairment specifically. While these instruments are designed to help officers identify driving impairment in general (irrespective of cause), prior empirical validation work has almost exclusively involved alcohol-induced impairment. This study will be conducted within a realistic, closed-course driving environment and it seeks to validate the same instruments currently used by law enforcement to detect cannabis-induced driving impairment against a second, independent, behavioral standard for driving impairment: a comprehensive driver evaluation adapted from the same set of driver tests that Californians must pass upon application for an original license, or (in certain instances) when referred to the Department of Motor Vehicles (DMV) for evaluation of their ability to safely operate a non-commercial class of motor vehicle (here referred to as the Modified Driver Performance Evaluation or MDPE). This study seeks to answer the following research questions: I. How accurately do behavioral assessments used by officers distinguish between drivers impaired by cannabis and drivers not impaired by cannabis? II. How does cannabis affect real-world (as opposed to simulated) driving performance? ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06059677
Study type	Interventional
Source	California Department of Motor Vehicles
Contact	Dario LM Sacchi, PhD
Phone	(916) 818 5312
Email	dario.sacchi2@dmv.ca.gov
Status	Recruiting
Phase	Phase 2
Start date	October 3, 2023
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05537116` - Evaluation of an Interactive Mobile Phone-Based Brief Intervention to Reduce Substance-Impaired Driving	N/A
Completed	`NCT03169855` - Validation of Mesopic and Photopic Contrast Vision Tests With Respect to Nighttime Driving Ability
Recruiting	`NCT06111989` - Fitness to Drive Among Stroke Patients
Completed	`NCT04587609` - Reducing Cell Phone Use While Driving Among High Risk UBI Auto Policy Holders	N/A
Completed	`NCT03656029` - Dose-response of Cannabis and Driving	Phase 2
Completed	`NCT04330196` - Effect of Postprandial Hyperinsulinaemic Hypoglycaemia on Driving Performance.	N/A
Completed	`NCT03353922` - Driving Simulation to Assess Non-Sedative Effects of Tolperisone	Phase 1
Completed	`NCT04948385` - Driving Performance After Deep Sedation for Outpatient Endoscopy	Phase 4
Completed	`NCT03335735` - Smartphone-paired Breathalyzers and Loss- and Gain-framed Texts for Reducing Drinking and Driving	N/A
Not yet recruiting	`NCT05703360` - Effectiveness of AV-stimulation in Immersive VR to Improve Visual Perception and Driving Performance	N/A
Active, not recruiting	`NCT03581058` - Neural Correlates of Driving and Cannabis	Phase 1
Withdrawn	`NCT05273658` - Effects of Cannabis/Alcohol on Driving Performance and Field Sobriety Tests	Phase 1/Phase 2
Completed	`NCT04648735` - Driving Evaluation and Fitness for Persons With Cognitive Impairments	N/A
Completed	`NCT03195608` - Using Advanced Driver Assistance Systems (ADAS) as an Intervention Strategy for Drivers With Parkinson's Disease	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Cannabis Consumption and Driving Impairment Assessment on a Closed Course

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms